Potential role of blood microRNAs as non-invasive biomarkers for early detection of asymptomatic coronary atherosclerosis in obese children with metabolic syndrome

Medical Hypotheses

Volumn 79, Issue 6, 2012, Pages 889-893

  Omran, Ahmed ^a,b   Elimam, Dalia ^a   He, Fang ^b   Peng, Jing ^b   Yin, Fei ^b  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ARTICLE; ASYMPTOMATIC DISEASE; AUTOPSY; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHILDHOOD OBESITY; CORONARY ARTERY ATHEROSCLEROSIS; EARLY DIAGNOSIS; HEART FUNCTION; HEART INFARCTION; HUMAN; METABOLIC SYNDROME X; NON INVASIVE PROCEDURE; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; CHILD; CORONARY ARTERY DISEASE; EARLY DIAGNOSIS; HUMANS; METABOLIC SYNDROME X; MICRORNAS; OBESITY;

EID: 84869084939     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.09.020     Document Type: Article

References (84)

1. de Onis M., Blössner M., Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr 2010, 92(5):1257-1264.
2. Campbell K., Waters E., O'Meara S., Kelly S., Summerbell C. Interventions for preventing obesity in children. Cochrane Database Syst Rev 2002, 2:CD001871.
3. Nemet D., Barkan S., Epstein Y., Friedland O., Kowen G., Eliakim A. Short- and long-term beneficial effects of a combined dietary-behavioral-physical activity intervention for the treatment of childhood obesity. Pediatrics 2005, 115(4):e443-e449.
4. Ogden C.L., Carroll M.D., Curtin L.R., Lamb M.M., Flegal K.M. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010, 303(3):242-249.
5. Akgun C., Dogan M., Akbayram S., Tuncer O., Peker E., Taskin G., et al. The incidence of asymptomatic hypertension in school children. J Nihon Med Sch 2010, 77(3):160-165.
6. Vikram N.K., Misra A., Pandey R.M., Luthra K., Wasir J.S., Dhingra V. Heterogeneous phenotypes of insulin resistance and its implications for defining metabolic syndrome in Asian Indian adolescents. Atherosclerosis 2006, 186(1):193-199.
7. Steinberger J., Daniels S.R. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003, 107(10):1448-1453.
8. Li Y., Yang X., Zhai F., Kok F.J., Zhao W., Piao J., et al. Prevalence of the metabolic syndrome in Chinese adolescents. Br J Nutr 2008, 99(3):565-570.
9. Perichart-Perera O., Balas-Nakash M., Schiffman-Selechnik E., BarbatoDosal A., Vadillo-Ortega F. Obesity increases metabolic syndrome risk Factors in school-aged children from an urban school in Mexico City. J Am Diet Assoc 2007, 107(1):81-91.
10. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004, 350(23):2362-2374.
11. McCrindle B.W. Cardiovascular consequences of paediatric obesity: Will there be a future epidemic of premature cardiovascular disease?. Paediatr Child Health 2007, 12(3):175-177.
12. Bartel D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136(2):215-233.
13. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105(30):10513-10518.
14. Yu Z., Han S., Hu P., Zhu C., Wang X., Qian L., et al. Potential role of maternal serum microRNAs as a biomarker for fetal congenital heart defects. Med Hypotheses 2011, 76(3):424-426.
15. Bai Y., Wang L., Sun L., Ye P., Hui R. Circulating microRNA-26a: potential predictors and therapeutic targets for non-hypertensive intracerebral hemorrhage. Med Hypotheses 2011, 77(4):488-490.
16. Wang L.L., Huang Y., Wang G., Chen S.D. The potential role of microRNA-146 in Alzheimer's disease: biomarker or therapeutic target?. Med Hypotheses 2012, 78(3):398-401.
17. Ge Y., Xiao L., Chen X., Peng Y., Sun L., Liu F. MicroRNAs in peritoneal dialysis effluent are promising biomarkers for peritoneal fibrosis in peritoneal dialysis patients. Med Hypotheses 2012, 78(1):155-156.
18. Hoekstra M., van der Lans C.A., Halvorsen B., Gullestad L., Kuiper J., Aukrust P., et al. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun 2010, 394(3):792-797.
19. Fichtlscherer S., De Rosa S., Fox H., Schwietz T., Fischer A., Liebetrau C., et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010, 107(5):677-684.
20. Palinski W., Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 2002, 16(11):1348-1360.
21. McNamara J.J., Molot M.A., Stremple J.F., Cutting R.T. Coronary artery disease in combat casualties in Vietnam. JAMA 1971, 216(7):1185-1187.
22. Berenson G.S., Wattigney W.A., Tracy R.E., Newman W.P., Srinivasan S.R., Webber L.S., et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol 1992, 70(9):851-858.
23. Zieske A.W., Malcom G.T., Strong J.P. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med 2002, 21(2):213-237.
24. Raj M. Obesity and cardiovascular risk in children and adolescents. Indian J Endocrinol Metab 2012, 16(1):13-19.
25. I'Allemand D., Wiegand S., Reinehr T., Müller J., Wabitsch M., Widhalm K., et al. Cardiovascular risk in 26,008 European overweight children as established by a multicenter database. Obesity (Silver Spring) 2008, 16(7):1672-1679.
26. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italien G.J., Pio J.R., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110(10):1245-1250.
27. Butler J., Mooyaart E.A., Dannemann N., Bamberg F., Shapiro M.D., Ferencik M., et al. Relation of the metabolic syndrome to quantity of coronary atherosclerotic plaque. Am J Cardiol 2008, 101(8):1127-1130.
28. Dawson J.D., Sonka M., Blecha M.B., Lin W., Davis P.H. Risk factors associated with aortic and carotid intima-media thickness in adolescents and young adults: the muscatine offspring study. J Am Coll Cardiol 2009, 53(24):2273-2279.
29. Ozcetin M., Celikyay Z.R., Celik A., Yilmaz R., Yerli Y., Erkorkmaz U. The importance of carotid artery stiffness and increased intima-media thickness in obese children. S Afr Med J 2012, 102(5):295-299.
30. Mansoub S., Chan M.K., Adeli K. Gap analysis of pediatric reference intervals for risk biomarkers of cardiovascular disease and the metabolic syndrome. Clin Biochem 2006, 39(6):569-587.
31. Frohlich J, Al-Sarraf A. Cardiovascular risk and atherosclerosis prevention. Cardiovasc Pathol 2012 [Epub ahead of print].
32. Wald N.J., Law M., Watt H.C., Wu T., Bailey A., Johnson A.M., et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994, 343(8889):75-79.
33. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100(25):2473-2476.
34. Katugampola S.D., Maguire J.J., Kuc R.E., Wiley K.E., Davenport A.P. Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can J Physiol Pharmacol 2002, 80(5):369-374.
35. Boekholdt S.M., Hack C.E., Sandhu M.S., Luben R., Bingham S.A., Wareham N.J., et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006, 187(2):415-422.
36. Cushman M., Arnold A.M., Psaty B.M., Manolio T.A., Kuller L.H., Burke G.L., et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005, 112(1):25-31.
37. Lowe G.D., Sweetnam P.M., Yarnell J.W., Rumley A., Rumley C., Bainton D., et al. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004, 24(10):1957-1962.
38. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., Fowkes F.G. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007, 115(16):2119-2127.
39. Park C.S., Ihm S.H., Yoo K.D., Kim D.B., Lee J.M., Kim H.Y., et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. Am J Cardiol 2010, 105(9):1284-1288.
40. Ballantyne C.M., Hoogeveen R.C., Bang H., Coresh J., Folsom A.R., Heiss G., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109(7):837-842.
41. Cho D.Y., Kim K.N., Kim K.M., Lee D.J., Kim B.T. Combination of high-sensitivity C-reactive protein and homocysteine may predict an increased risk of coronary artery disease in Korean population. Chin Med J (Engl) 2012, 125(4):569-573.
42. Kampoli A.M., Tousoulis D., Papageorgiou N., Pallatza Z., Vogiatzi G., Briasoulis A., et al. Clinical utility of biomarkers in premature atherosclerosis. Curr Med Chem 2012, 19(16):2521-2533.
43. Tousoulis D., Androulakis E., Papageorgiou N., Briasoulis A., Siasos G., Antoniades C., et al. From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand. Trends Cardiovasc Med 2010, 20(5):153-164.
44. Bakogiannis C., Tousoulis D., Androulakis E., Briasoulis A., Papageorgiou N., Vogiatzi G., et al. Circulating endothelial progenitor cells as biomarkers for prediction of cardiovascular outcomes. Curr Med Chem 2012, 19(16):2504-2597.
45. Sinnaeve P.R., Donahue M.P., Grass P., Seo D., Vonderscher J., Chibout S.D., et al. Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease. PLoS One 2009, 4(9):e7037.
46. van Rooij E., Olson E.N. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007, 117(9):2369-2376.
47. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
48. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):906-997.
49. Cacchiarelli D., Legnini I., Martone J., Cazzella V., D'Amico A., Bertini E., et al. MiRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med 2011, 3(5):258-265.
50. Mizuno H., Nakamura A., Aoki Y., Ito N., Kishi S., Yamamoto K. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood based markers for muscular dystrophy. PLoS One 2011, 6(3):e18388.
51. Lai C.Y., Yu S.L., Hsieh M.H., Chen C.H., Chen H.Y., Wen C.C., et al. MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 2011, 6:e21635.
52. Roth P., Wischhusen J., Happold C., Chandran P.A., Hofer S., Eisele G., et al. A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 2011, 118(3):449-457.
53. Zampetaki A., Kiechl S., Drozdov I., Willeit P., Mayr U., Prokopi M., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010, 107(6):810-817.
54. Roth C., Rack B., Muller V., Janni W., Pantel K., Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010, 12(6):R90.
55. Hennessey P.T., Sanford T., Choudhary A., Mydlarz W.W., Brown D., Adai A.T., et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One. 2012, 7(2):e32307.
56. Moussay E., Wang K., Cho J.H., van Moer K., Pierson S., Paggetti J., et al. MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2011, 108(16):6573-6578.
57. Adachi T., Nakanishi M., Otsuka Y., Nishimura K., Hirokawa G., Goto Y., et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem 2010, 56(7):1183-1185.
58. Corsten M.F., Dennert R., Jochems S., Kuznetsova T., Devaux Y., Hofstra L., et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010, 3(6):406-499.
59. Wang G.K., Zhu J.Q., Zhang J.T., Li Q., Li Y., He J., et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010, 31(6):659-666.
60. Tijsen A.J., Creemers E.E., Moerland P.D., de Windt L.J., van der Wal A.C., Kok W.E., et al. Mir423-5p as a circulating biomarker for heart failure. Circ Res 2010, 106(6):1035-1039.
61. Xiao J., Jing Z.C., Ellinor P.T., Liang D., Zhang H., Liu Y., et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med. 2011, 24(9):159.
62. Reid G., Kirschner M.B., van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011, 80(2):108-193.
63. Mause S.F., Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010, 107(9):1047-1057.
64. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13(4):423-433.
65. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011, 108(12):5003-5008.
66. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumor growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10(12):1470-1476.
67. Gilad S., Meiri E., Yogev Y., Benjamin S., Lebanony D., Yerushalmi N., et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3(9):e3148.
68. Zhang B., Farwell M.A. MicroRNAs: a new emerging class of players for disease diagnostics and gene therapy. J Cell Mol Med 2008, 12(1):3-21.
69. De Smaele E., Ferretti E., Gulino A. MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res 2010, 1338:100-111.
70. Wittmann J., Jäck H.M. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta 2010, 1806(2):200-207.
71. de Planell-Saguer M., Rodicio M.C. Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta 2011, 699(2):134-152.
72. Liew C.C., Ma J. C, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006, 147(3):126-132.
73. Weber M, Baker MB, Patel RS, Quyyumi AA, Bao G, Searles CD. MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB. Cardiol Res Pract 2011;532915.
74. Zhi H., Wang L., Ma G., Ye X., Yu X., Zhu Y., et al. Polymorphisms of miRNAs genes are associated with the risk and prognosis of coronary artery disease. Clin Res Cardiol 2012, 101(4):289-296.
75. Heneghan H.M., Miller N., Kerin M.J. Role of microRNAs in obesity and the metabolic syndrome. Obes Rev 2010, 11(5):354-361.
76. Elmen J., Lindow M., Schutz S., Lawrence M., Petri A., Obad S., et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452(7189):896-899.
77. Tabuchi T., Satoh M., Itoh T., Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (Lond) 2012, 123(3):161-171.
78. Wang H., Lu H.M., Yang W.H., Luo C., Lu S.H., Zhou Y., et al. The influence of statin therapy on circulating microRNA-92a expression in patients with coronary heart disease. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2012, 24(4):215-218.
79. Fichtlscherer S., Zeiher A.M., Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?. Arterioscler Thromb Vasc Biol 2011, 31(11):2383-2390.
80. Creemers E.E., Tijsen A.J., Pinto Y.M. Circulating microRNAs: Novel Biomarkers and Extracellular Communicators in Cardiovascular Disease?. Circ Res 2012, 110(3):483-495.
81. Gao W., He H.W., Wang Z.M., Zhao H., Lian X.Q., Wang Y.S., et al. Plasma levels of lipometabolism related miR122 and miR370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis 2012, 11(1):55.
82. Contu R., Latronico M.V., Condorelli G. Circulating microRNAs as potential biomarkers of coronary artery disease: a promise to be fulfilled?. Circ Res 2010, 107(5):573-574.
83. Sondermeijer B.M., Bakker A., Halliani A., de Ronde M.W., Marquart A.A., Tijsen A.J., et al. Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*. PLoS One 2011, 6(10):e25946.
84. Hulsmans M., Sinnaeve P., Van der Schueren B., Mathieu C., Janssens S., Holvoet P. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J Clin Endocrinol Metab. 2012, 97(7):E1213-E1218.